| Courtney Lynn Glenn, DPM | |
|
1515 River Pl Ste 370, Braselton, GA 30517-5605 | |
| (770) 648-5040 | |
| (706) 780-5366 |
| Full Name | Courtney Lynn Glenn |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 12 Years |
| Location | 1515 River Pl Ste 370, Braselton, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831454750 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | POD001277 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Health Home Health | Gainesville, GA | Home health agency |
| Northeast Georgia Medical Center, Inc | Gainesville, GA | Hospital |
| Barrow Regional Medical Center | Winder, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Courtney Glenn, Dpm Llc | 8820307150 | 2 |
News Archive
Using inexpensive air filters may help reduce cardiovascular disease risk that results from exposure to air pollution, according to researchers from Canada, who studied healthy adultsliving in a small community in British Columbia where wood burning stoves are the main sources of pollution.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Despite recent moves by some states to restrict access to abortion, more Americans now support a woman's right to choose than they did two years ago, a new Harris Interactive/HealthDay poll finds.
Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.
› Verified 9 days ago
| Provider Name | Courtney Glenn, Dpm Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1306221106 PECOS PAC ID: 8820307150 Enrollment ID: O20151027001571 |
News Archive
Using inexpensive air filters may help reduce cardiovascular disease risk that results from exposure to air pollution, according to researchers from Canada, who studied healthy adultsliving in a small community in British Columbia where wood burning stoves are the main sources of pollution.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Despite recent moves by some states to restrict access to abortion, more Americans now support a woman's right to choose than they did two years ago, a new Harris Interactive/HealthDay poll finds.
Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Courtney Lynn Glenn, DPM 1515 River Pl Ste 370, Braselton, GA 30517-5605 Ph: (770) 648-5040 | Courtney Lynn Glenn, DPM 1515 River Pl Ste 370, Braselton, GA 30517-5605 Ph: (770) 648-5040 |
News Archive
Using inexpensive air filters may help reduce cardiovascular disease risk that results from exposure to air pollution, according to researchers from Canada, who studied healthy adultsliving in a small community in British Columbia where wood burning stoves are the main sources of pollution.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Despite recent moves by some states to restrict access to abortion, more Americans now support a woman's right to choose than they did two years ago, a new Harris Interactive/HealthDay poll finds.
Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.
› Verified 9 days ago
Chateau Foot And Ankle Center, Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1515 River Pl, Suite 140, Braselton, GA 30517 Phone: 770-648-5040 | |
Gemma P English, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1515 River Pl Ste 370, Braselton, GA 30517 Phone: 770-648-5040 Fax: 706-780-5366 | |
Dr. Bradley David Castellano, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1515 River Pl, Suite 140, Braselton, GA 30517 Phone: 770-648-5040 |